Altimmune's Strategic Moves and Insider Confidence

Core Insights - The CEO of Altimmune, Durso Jerome Benedict, purchased 20,000 shares at approximately $3.54 per share, increasing his total holdings to 32,500 shares, indicating strong confidence in the company's future [1][5] - Altimmune is preparing for a pivotal Phase 3 program for pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH), which aligns with the company's strategic focus on liver disease treatments [2][5] - The unique approach of pemvidutide, featuring "balanced one-to-one agonism of glucagon and GLP-1," may differentiate Altimmune in the treatment landscape, potentially reducing liver fat and aiding in weight loss [3][5] Financial Overview - The current stock price of ALT is $3.54, with a slight increase of 0.99% or $0.035, and has fluctuated between $3.41 and $3.74 throughout the day [4] - Over the past year, ALT reached a high of $7.73 and a low of $2.9, with a market capitalization of approximately $312.4 million and a trading volume of 5,385,353 shares [4]